Inferra AIResearch Tools

Inferra AI / Company / CDNA

CareDx, Inc.

CDNA · Health Care

Last earnings Oct 29, 2026

Key results

Revenuequarter

$100.1 million

Revenue of $100.1 million, an increase of 21% year-over-year Testing services

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

revenue of $72.2 million, an increase of 19% year-over-year Testing services volume of 50,300, an increase of 13% year-over-year

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

GAAP net incomequarter

$1.7 million

GAAP net income of $1.7 million, compared to a GAAP net loss of $10.6 million in the third quarter of 2024 Adjusted EBITDA of $15.3 million, compared to $6.9 million in the third quarter of 2024 Cash, cash equivalents and marketable securities of $194.2 million as of September 30, 2025

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Total revenuequarter

$100.1 million

Q3 2025 Financial Results Total revenue was $100.1 million compared to $82.9 million in the third quarter of 2024, an increase of 21%.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Testing services revenue was $72.2 million, compared to $60.8 million in the third quarter of 2024, an increase of 19%.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Digital Solutions revenuequarter

$15.4 million

Patient and Digital Solutions revenue was $15.4 million, compared to $11.9 million in the third quarter of 2024, an increase of 30%.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Product revenuequarter

$12.5 million

Product revenue was $12.5 million, an increase of 22% compared to $10.2 million in the third quarter of 2024.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

GAAP net income was $1.7 million compared to GAAP net loss of $10.6 million in the third quarter 2024.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

AI analysis

Q3 2025 · reported Nov 4, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2025
$100.1M
+20.7% +$17M vs year ago computed from stated figures
EX-99 · Nov 4, 2025
GAAP net income · Q3 2025
$1.7M
-75.4% -$5M vs year ago computed from stated figures
EX-99 · Nov 4, 2025
Total revenue · Q3 2025
$100.1M
+20.7% vs year ago computed from stated figures
EX-99 · Nov 4, 2025
Digital Solutions revenue · Q3 2025
$15.4M
+29.4% vs year ago computed from stated figures
EX-99 · Nov 4, 2025

The quarter in charts

Revenue — quarterly

As stated

041.783.3125$82.9MSame quarter last year$100.1MQ3 2025

EX-99 · Nov 4, 2025 Statement values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Nov 4, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Segment mix

Business-unit revenue, as stated

06.6713.320$15.4MDigital Solutions$12.5MProduct

Segment revenue figures as stated in the event record.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue$100.1 million—$82.9 million
GAAP net income$1.7 million—$6.9 million
Total revenue$100.1 million—$82.9 million
Digital Solutions revenue$15.4 million—$11.9 million
Product revenue$12.5 million—$10.2 million

EX-99 · Nov 4, 2025

Guidance · company-stated

revenue$372 million
EBITDA

“to be in the range of $35 million to $39 million”

Midpoint vs latest-quarter revenue+271.6%computed from stated figures

Guidance stated in the release for the full year 2025; figures as stated.

Next earningsNo verified date on fileNo date is estimated or imported

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue +271.6% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

CareDx, Inc. Q3 2025 — Revenue of $100.1 million, an increase of 21% year-over-year Testing services

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

revenue: “revenue to be in the range of $372 million to $376 million”

EBITDA: “EBITDA to be in the range of $35 million to $39 million”

revenue (“the full year 2025”)
“2025 Guidance For the full year 2025, CareDx now expects revenue to be in the range of $372 million to $376 million, compared to the $367 million to $373 million range that was previously disclosed.”

EBITDA (“full year 2025”)
“The Company now expects full year 2025 adjusted EBITDA to be in the range of $35 million to $39 million, compared to the $29 million to $33 million range that was previously disclosed.”

Guidance stated in the release for the full year 2025; figures as stated.

Strategy & priorities

(Nasdaq CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Our strategy to extend that leadership and deliver long-term profitable growth is guided by putting our customers at the center of everything we do, and we believe that strategy is working.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

, headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

We define non-GAAP net income and per share results as the GAAP net income (loss) and per share results excluding the impacts of stock-based compensation expense acquisition-related amortization of purchased intangible assets and related tax effects costs involved with completing an acquisition changes in estimated fair value of contingent consideration litigation settlement expense transformational initiative costs and certain other charges presented in the reconciliation in this release.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Risks & headwinds

We define non-GAAP net income and per share results as the GAAP net income (loss) and per share results excluding the impacts of stock-based compensation expense acquisition-related amortization of purchased intangible assets and related tax effects costs involved with completing an acquisition changes in estimated fair value of contingent consideration litigation settlement expense transformational initiative costs and certain other charges presented in the reconciliation in this release.

SEC original ↗CareDx, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Documents

Earnings deck slides

0 decks with slide view

CareDx, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

35 documents

Earnings releases

16 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for CareDx, Inc. are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention CareDx, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.